Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.
1988
Verapamil and Doxorubicin Resistance in Melanoma Cells
publication
Author Information
Author(s): F. Formelli, R. Supino, L. Cleris, M. Mariani
Hypothesis
Does the combination of verapamil and doxorubicin affect the development of drug resistance in melanoma cells?
Conclusion
The study found that melanoma cells treated with doxorubicin and verapamil became more resistant and exhibited characteristics of more differentiated cells.
Supporting Evidence
- Cells selected by doxorubicin and verapamil were more resistant than those selected by doxorubicin alone.
- These cells showed features associated with more differentiated cells, such as higher melanin content and more dendrite-like structures.
- The B16-DX.VRP line produced fewer metastases compared to the original B16 tumor.
Takeaway
When melanoma cells are treated with a combination of two drugs, they become tougher and show more features like normal cells.
Want to read the original?
Access the complete publication on the publisher's website